NTRA stock forecast
Our latest prediction for Natera, Inc.'s stock price was made on the Sept. 18, 2018 when the stock price was at 24.47$.
In the short term (2weeks), NTRA's stock price should outperform the market by 0.18%. During that period the price should oscillate between -7.83% and +8.91%.
In the medium term (3months), NTRA's stock price should underperform the market by -0.32%. During that period the price should oscillate between -18.42% and +24.63%.Get email alerts
About Natera, Inc.
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
At the moment the company generates 286M USD in revenues.
On its last earning announcement, the company reported a loss of -1.84$ per share.
The book value per share is -0.36$
Three months stock forecastSept. 18, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|